Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05101629
Title Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab Therapy
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.